Life Sciences Voice’s Post

Even novice investors are aware that Novo Nordisk and Eli Lilly are the clear winners in the GLP-1 and weight loss drug revolution. What they may not know is that biotech and pharma companies across the globe are studying and developing cutting-edge drugs varying in administration, dose frequency, and mechanism of treatment to address the obesity epidemic. In our latest blog, we highlight five lesser-known OZEM holdings from the U.S., Denmark, Japan, and Taiwan, which are all at the forefront of what we believe is game-changing innovation in health care. Blog: https://lnkd.in/emqxkDrp For current fund holdings: https://lnkd.in/ezVTUDUz

Danish drugmaker Novo Nordisk, the firm behind the highly sought-after diabetes treatment Ozempic and obesity treatment Wegovy, will spend $4.1bn on a new #factory in North Carolina. The 1.4 million-sq-ft fill-and-finishing plant in Clayton will add 1,000 new jobs to the 2,500 employees already working at its facilities in the area. The company estimates that 2,000 external #contractors will work at the site at the height of #construction. The plant aims to achieve #LEED Gold certification, with green features such as roof-top solar panels and water reuse. Lars Fruergaard Jørgensen, Novo Nordisk’s president, said: “This is yet another real signal of our efforts to scale up our #production to meet the growing global need for our life-changing medicines and the patients of tomorrow." Foundation work is underway. The plant is due to start producing from 2027. Novo Nordisk says it invested $3.9bn in US #manufacturing last year. The company has faced criticism for vastly overcharging Americans for its drugs. A recent study found it charged $936 for a month’s supply of Ozempic in the US, 10 times what it charged for the same in the UK. A month’s supply of Wegovy costs $1,349 in the US, but just $328 in #Germany.

🚨Novo Nordisk’s Diabetes & Obesity Treatments Face Critical Patent Expirations in the US and EU🚨 ⏩ As a leader in diabetes and obesity care, Novo Nordisk is approaching key patent expirations for several of its flagship treatments, which could significantly impact the competitive landscape ⏪ Key Patent Expiration Dates: ➡️ Tresiba, Ryzodeg, Xultophy: US: 2029 | EU: 2028 ➡️ Fiasp: US & EU: 2030 (formulation patent; active ingredient patent has already expired) ➡️ Ozempic, Rybelsus, Wegovy: US: 2032 | EU: 2031 🔍What’s at Stake? 1️⃣ Increased Generic Competition: The entry of generics could drive down costs for patients but place pressure on Novo Nordisk’s revenue streams 2️⃣ Innovation Pressure: Novo Nordisk will need to accelerate its R&D to stay ahead, potentially bringing new drug formulations, delivery methods, and lifestyle integration technologies 3️⃣ Healthcare Opportunities: As these patents expire, more patients may gain access to affordable, life-changing treatments, improving global healthcare outcomes 💡 As the landscape shifts, Novo Nordisk has the opportunity to lead through innovation and ensure patients continue receiving cutting-edge care.📈 What’s your take on how these expirations will impact the industry and patient access❓Share your insights below❗🤔 For more information, reach out to Octavus Consulting and Himanshu Sehgal #Pharma #HealthcareInnovation #DiabetesCare #ObesityCare #PatentExpiry #GenericDrugs #PatientAccess #NovoNordisk #Biotech #Pharmaceuticals #R&D #HealthTech #AffordableHealthcare #DrugDevelopment

💡 Patent expirations bring both challenges and opportunities for Novo Nordisk and the broader pharmaceutical industry. While there is a risk of revenue loss due to increased generic competition, these expirations also spur innovation and expand market access: 1️⃣ Promoting Innovation: With patents expiring, there's a natural drive for companies to develop new formulations, delivery methods, or even breakthrough therapies to maintain their competitive edge. This ensures that patients benefit from cutting-edge treatments as the industry evolves. 2️⃣ Increased Research for Generics: The opportunity for generic manufacturers to develop affordable versions of life-changing treatments can significantly lower costs for patients, especially in the diabetes and obesity sectors. This contributes to improved accessibility of essential medications globally. 3️⃣ Market Expansion: With more affordable generics, the market widens, allowing more patients to receive the care they need. This fosters health equity by making effective treatments more accessible in low- and middle-income countries. In conclusion, while Novo Nordisk faces pressure from patent expirations, the opportunity to lead with innovation and expand patient access creates a win-win scenario for the healthcare system and the global patient population. 📊 What are your thoughts on the balance between innovation and generic competition? Share your insights! Ruchi Sengar Thanks for such nice representations and analysis #HealthcareInnovation #Pharma #PatentExpiry #Generics #Innovation #PatientAccess #NovoNordisk #R&D #AffordableHealthcare

🌟 Exciting Prediction: Novo Nordisk, known for its diabetes and obesity treatment Ozempic, is under scrutiny for price inconsistencies. As investigations reveal the actual cost of semaglutide is lower, changes may be on the horizon. 🧐 General Commentary: The misalignment between production costs and retail prices highlights an essential need for transparency and fairness in the pharmaceutical industry. It raises questions on accessibility to life-saving treatments and the importance of ethical pricing practices. Key Points: - Upcoming adjustments in pricing strategies could revolutionize treatment accessibility for diabetes and obesity patients. - Increased transparency in the pharmaceutical sector could lead to improved public trust and accountability. - The debate on healthcare affordability exposes larger systemic issues that need addressing for the benefit of all stakeholders. Innovation within the industry, including fair pricing models, can lead to a more sustainable and inclusive future for healthcare. Let's stay tuned for the potential groundbreaking changes that could arise from this pivotal moment in Novo Nordisk's journey. #PharmaceuticalIndustry #Healthcare #PriceTransparency #InnovationForAllhttps://lnkd.in/e_PtrW3k

#ACROHighlights [Featured Product 🌟 Tirzepatide: Semaglutide's Top Contender Approved in China! Great news from the biotech world! On May 21st, the NMPA officially announced the approval of Eli Lilly's Tirzepatide for marketing in China. 🎉 2023 has seen Novo Nordisk's semaglutide shine, but Eli Lilly's tirzepatide is a formidable competitor. Both drugs are at the forefront of glucose-lowering and weight-reducing treatments, highlighting the industry's focus on long-acting, oral administration, multi-targeting, combination therapy, and multiple indications. At ACROBiosystems, we are committed to supporting the development of innovative diabetes and weight loss therapies. Our high-quality GLP-1R products are here to accelerate your research! 🧬💪 Learn more about our offerings: https://smpl.is/98zwg #Biotech #PharmaNews #Tirzepatide #Semaglutide #DiabetesTreatment #WeightLoss #ACROBiosystems #Innovation #Healthcare

When good drugs do not move forward for strategic, commercial or other reasons, someone is missing on a potentially life-changing solution. Rescuing and repositioning drugs has relatively high ROI for all stakeholders. Looking forward to the SAPA conference for more opportunities to partner.

🔍 Insights long-time readers of BioCentury often share with me 🔍 How much they appreciate following the "bread-crumbs of analysis." Here's a sample tracking Roche’s journey into the obesity market: 🔹 DEC 4, 2023 After $2.7B takeout of Carmot Therapeutics, Inc., a bigger investment for Roche will come with development programs and commercial buildup to compete with Novo Nordisk and Eli Lilly and Company. 🔹 MAY 16, 2024 Roche's CT-388 yields promising weight loss; tolerability data will be key to determining its competitive profile. 🔹 JULY 17, 2024 Early data suggest best-in-class potential of Roche's oral GLP-1 for obesity 🔍📊🔍 Every day = new bread crumbs to follow 🔍📊🔍 Links to the stories above in the comments below. #biotech #obesity #roche #biopharma #GLP1

The top 10 pharma R&D budgets for 2023 After nearly a decade as No. 1, Roche has finally been knocked off the top spot of our annual list of the biggest research and development budgets in pharma, sent spinning down the ladder by a whopping $30 billion tally from Merck & Co. 2023 was a year of recalibration, with COVID-19 fading from pharma’s forefront as the obesity market took hold. The explosion was driven by Mounjaro from Eli Lilly (No. 7) and Ozempic and Wegovy from Novo Nordisk, which did not make our list. #pharma #research #development #R&D #top10 #budget https://lnkd.in/gcRj6vpu

Exciting news! Biocon has teamed up with Biomm to bring its innovative diabetes drug to Brazil 🇧🇷. 💊🌎 🗒Under the terms of the agreement, Biocon will undertake the development, manufacturing, and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market. Benefits of the Partnership: 📈 Biocon: Expands their global footprint beyond the US and Europe. Access to the Brazilian market with a potential value of $580 million (according to IQVIA data). Biomm: Adds a novel diabetes treatment to their portfolio. Strengthens their position in the Brazilian market for complex biotech drugs. Overall, this partnership is a win-win for all parties involved. Biocon gains access to a new market, Biomm gets a valuable product, and Brazilian diabetes patients potentially benefit from a new treatment option. #Biocon #Biomm #DiabetesTreatment #HealthcareInnovation